Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 21Gastrointestinal 10NET 9Genitourinary 4Breast 3Thoracic 2Plasma cell 2Lymphoid 2Dermatologic 2Sarcoma 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1CNS 1

Conditions

Carcinoma, Intraductal, Noninfiltrating 2Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Trastuzumab 692Paclitaxel 678Cyclophosphamide 634Docetaxel 553Capecitabine 467Letrozole 407Carboplatin 392Fulvestrant 377Doxorubicin 330Tamoxifen 288pembrolizumab 270Anastrozole 252Epirubicin 249exemestane 238pertuzumab 226Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × pasireotide × Breast × Clear all
NCT01372618 2017-12-27

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor

NYU Langone Health

Phase 1/2 Terminated
9 enrolled 3 charts
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT01356862 2017-01-25

SOM 230

Alliance Pour La Recherche en Cancerologie

Phase 2 Completed
91 enrolled
Breast

Breast Neoplasms

NCT01372644 2016-12-05

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial

NYU Langone Health

Phase 1 Completed
15 enrolled
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡